[go: up one dir, main page]

WO2013168006A3 - Compositions and methods for the treatment of local pain - Google Patents

Compositions and methods for the treatment of local pain Download PDF

Info

Publication number
WO2013168006A3
WO2013168006A3 PCT/IB2013/051268 IB2013051268W WO2013168006A3 WO 2013168006 A3 WO2013168006 A3 WO 2013168006A3 IB 2013051268 W IB2013051268 W IB 2013051268W WO 2013168006 A3 WO2013168006 A3 WO 2013168006A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
treatment
neuralgia
compositions
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/051268
Other languages
French (fr)
Other versions
WO2013168006A2 (en
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellix Bio Pvt Ltd
Original Assignee
Cellix Bio Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Pvt Ltd filed Critical Cellix Bio Pvt Ltd
Priority to JP2015510898A priority Critical patent/JP2016508956A/en
Priority to SG11201407323WA priority patent/SG11201407323WA/en
Priority to CA2873138A priority patent/CA2873138A1/en
Priority to CN201380030659.5A priority patent/CN105612155A/en
Priority to AU2013257727A priority patent/AU2013257727B2/en
Priority to EP13788349.2A priority patent/EP2882745A2/en
Publication of WO2013168006A2 publication Critical patent/WO2013168006A2/en
Priority to ZA2014/08055A priority patent/ZA201408055B/en
Anticipated expiration legal-status Critical
Publication of WO2013168006A3 publication Critical patent/WO2013168006A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of local pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of infiltration, nerve block, epidural, intrathecal anesthesia, pain, severe pain, chronic pain, chemotherapy induced pain, neuropathic pain, post herpetic neuralgia, neuralgia, motor neurone disease, diabetic neuropathy, postheipetic neuralgia, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, cancer pain and Sower back pain.
PCT/IB2013/051268 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain Ceased WO2013168006A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2015510898A JP2016508956A (en) 2012-05-10 2013-02-16 Compositions and treatments for the treatment of local pain
SG11201407323WA SG11201407323WA (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain
CA2873138A CA2873138A1 (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain
CN201380030659.5A CN105612155A (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain
AU2013257727A AU2013257727B2 (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain
EP13788349.2A EP2882745A2 (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain
ZA2014/08055A ZA201408055B (en) 2012-05-10 2014-11-04 Compositions and methods for the treatment of local pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1843CH2012 2012-05-10
IN1843/CHE/2012 2012-05-10

Publications (2)

Publication Number Publication Date
WO2013168006A2 WO2013168006A2 (en) 2013-11-14
WO2013168006A3 true WO2013168006A3 (en) 2016-09-01

Family

ID=54193695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/051268 Ceased WO2013168006A2 (en) 2012-05-10 2013-02-16 Compositions and methods for the treatment of local pain

Country Status (8)

Country Link
EP (1) EP2882745A2 (en)
JP (1) JP2016508956A (en)
CN (1) CN105612155A (en)
AU (1) AU2013257727B2 (en)
CA (1) CA2873138A1 (en)
SG (1) SG11201407323WA (en)
WO (1) WO2013168006A2 (en)
ZA (1) ZA201408055B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8361067B2 (en) 2002-09-30 2013-01-29 Relievant Medsystems, Inc. Methods of therapeutically heating a vertebral body to treat back pain
WO2010036865A2 (en) 2008-09-26 2010-04-01 Relievant Medsystems, Inc. Systems and methods for navigating an instrument through bone
AU2012362524B2 (en) 2011-12-30 2018-12-13 Relievant Medsystems, Inc. Systems and methods for treating back pain
US10588691B2 (en) 2012-09-12 2020-03-17 Relievant Medsystems, Inc. Radiofrequency ablation of tissue within a vertebral body
CA2889478C (en) 2012-11-05 2020-11-24 Relievant Medsystems, Inc. Systems and methods for creating curved paths through bone and modulating nerves within the bone
US9724151B2 (en) 2013-08-08 2017-08-08 Relievant Medsystems, Inc. Modulating nerves within bone using bone fasteners
BR112019013192A2 (en) * 2016-12-26 2019-12-10 Cellix Bio Private Ltd compound and pharmaceutical composition
EP4027912B1 (en) 2019-09-12 2024-12-18 Relievant Medsystems, Inc. Systems for tissue modulation
WO2022011115A1 (en) 2020-07-10 2022-01-13 Relievant Medsystems, Inc. Vertebral denervation in conjunction with vertebral fusion
US12082876B1 (en) 2020-09-28 2024-09-10 Relievant Medsystems, Inc. Introducer drill
WO2022140712A1 (en) 2020-12-22 2022-06-30 Relievant Medsystems, Inc. Prediction of candidates for spinal neuromodulation
US12433668B1 (en) 2021-11-08 2025-10-07 Relievant Medsystems, Inc. Impedance stoppage mitigation during radiofrequency tissue ablation procedures
GB202305212D0 (en) * 2023-04-06 2023-05-24 Elixa Mediscience Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1126435A (en) * 1993-06-28 1996-07-10 阿斯特拉公司 Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade
CN1279607A (en) * 1997-11-19 2001-01-10 达尔文发现有限公司 Anaesthetic formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187813A (en) * 1995-05-01 1998-07-15 斯科舍集团有限公司 Fatty acid esters as bioactive compounds
GB9704349D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use
RS51031B (en) * 2001-04-30 2010-10-31 Trommsdorff Gmbh & Co.Kg.Arzneimittel PHARMACEUTICAL ACTIVE ESTRI URIDINA
USRE46397E1 (en) * 2007-11-07 2017-05-09 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US20120022147A1 (en) * 2011-08-17 2012-01-26 Krisani Biosciences (P) Ltd 2, 6 xylidine derivatives for the treatment of pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1126435A (en) * 1993-06-28 1996-07-10 阿斯特拉公司 Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade
CN1279607A (en) * 1997-11-19 2001-01-10 达尔文发现有限公司 Anaesthetic formulation

Also Published As

Publication number Publication date
CN105612155A (en) 2016-05-25
WO2013168006A2 (en) 2013-11-14
AU2013257727B2 (en) 2016-04-28
SG11201407323WA (en) 2014-12-30
JP2016508956A (en) 2016-03-24
ZA201408055B (en) 2016-03-30
CA2873138A1 (en) 2013-11-14
EP2882745A2 (en) 2015-06-17
AU2013257727A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
WO2013168006A3 (en) Compositions and methods for the treatment of local pain
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
MX2013012776A (en) Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors.
PH12016500573A1 (en) Compound having somatostatin agonistic activity and pharmaceutical uses thereof
WO2014141057A3 (en) Compositions and methods for the treatment of cancer
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
MX2022005523A (en) Compositions and methods for the treatment of fungal infections.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2014006529A3 (en) Compositions and methods for the treatment of moderate to severe pain
WO2013168004A3 (en) Compositions and methods for the treatment of fibromyalgia pain
WO2020075023A3 (en) Compositions and methods for the treatment of parkinson's disease
EA033083B1 (en) Cyclic compounds
WO2013167989A3 (en) Compositions and methods for the treatment of neurological disorders
WO2014195850A3 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014097137A3 (en) Compositions and methods for the treatment of seizures and neurologic diseases
WO2014106804A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
WO2014068506A3 (en) Compositions and methods for the treatment of autoimmune diseases
WO2014068459A3 (en) Compositions and methods for the treatment of pain and neurological diseases
WO2013175344A3 (en) Compositions and methods for treatment of peridontitis and rheumatoid arthritis
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
WO2013168005A3 (en) Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2014122621A3 (en) Compositions and methods for the treatment of metabolic conditions and neuromuscular diseases
WO2014068461A3 (en) Compositions and methods for the treatment of acute inflammation
WO2017208088A3 (en) Compositions and methods for the treatment of parkinson's disease

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2873138

Country of ref document: CA

Ref document number: 2015510898

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013788349

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2013257727

Country of ref document: AU

Date of ref document: 20130216

Kind code of ref document: A